Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Niagen Bioscience, Inc. - Common Stock (NQ:NAGE)

9.500 -0.180 (-1.86%)
Streaming Delayed Price Updated: 2:18 PM EDT, Sep 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Niagen Bioscience, Inc. - Common Stock

AboutNADⓇ Debuts as the Leading Online Resource for Scientific Advancements in NAD+
From Niagen Bioscience, Inc
Via Business Wire
Niagen Bioscience, Inc. Reports Second Quarter 2025 Financial Results and Increases Full Year Outlook
From Niagen Bioscience, Inc.
Via Business Wire
Niagen Bioscience to Present at Canaccord Genuity’s 45th Annual Growth Conference
From Niagen Bioscience, Inc
Via Business Wire
Niagen Bioscience to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025
From Niagen Bioscience, Inc
Via Business Wire
Niagen Bioscience Announces the Debut of Tru Niagen® and Niagen IV at Equinox Hotel New York
From Niagen Bioscience, Inc
Via Business Wire
Niagen Bioscience Secures Exclusive License to Develop and Commercialize its NAD+ Precursor, Patented Nicotinamide Riboside (Niagen®), as a Potential Parkinson’s Disease Therapy in Agreement with Haukeland University Hospital in Bergen, Norway
From Niagen Bioscience, Inc
Via Business Wire
Niagen Bioscience to Participate at the Roth 15th Annual London Conference
From Niagen Bioscience, Inc
Via Business Wire
Niagen Bioscience to Participate in the BIO 2025 International Convention
From Niagen Bioscience, Inc
Via Business Wire
Niagen Bioscience Announces First-Ever Peer-Reviewed Study Highlighting the Potential of Nicotinamide Riboside (NR) for Werner Syndrome, a Rare Genetic Disorder
From Niagen Bioscience, Inc
Via Business Wire
Niagen Bioscience to Present at Oppenheimer’s 25th Annual Consumer Growth and E-Commerce Conference
From Niagen Bioscience, Inc
Via Business Wire
Niagen Bioscience, Inc. Reports First Quarter 2025 Financial Results and Increases Outlook
From Niagen Bioscience, Inc
Via Business Wire
Niagen Bioscience Announces Pharmaceutical-Grade Niagen® IV Is Now Available in Almost 600 Clinics Nationwide
From Niagen Bioscience, Inc
Via Business Wire
Niagen Bioscience Welcomes Dr. Pinchas Cohen to Scientific Advisory Board
From Niagen Bioscience, Inc
Via Business Wire
Niagen Bioscience to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025
From Niagen Bioscience, Inc
Via Business Wire
Niagen Bioscience Confirms Its Operations Remain Unaffected by New Tariffs
From Niagen Bioscience, Inc
Via Business Wire
Niagen Bioscience Secures U.S. Patent for the Composition of Matter for Nicotinamide Riboside (NR) Salt Forms
From Niagen Bioscience, Inc
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.